Life Sciences

  • February 09, 2026

    Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages

    Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.

  • February 09, 2026

    Defendant Mix-Up Ends Biotech FCA Suit, For Now

    A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.

  • February 09, 2026

    Italian Biathlete Lodges Appeal Of Olympic Doping Ban

    Italian biathlete Rebecca Passler, who was booted from the Olympic team last week after a positive doping test, has appealed the decision to the Court of Arbitration for Sport, asserting that the test result arose from a contamination issue.

  • February 09, 2026

    Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.

    The Federal Circuit on Monday reversed a lower court's ruling that Abiomed Inc. hasn't infringed five patents on blood pump systems and methods, while backing the part of the decision that cleared the medical device technology company of allegations it infringed a different patent.

  • February 09, 2026

    Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1

    Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.

  • February 09, 2026

    High Court Asked To Take Up Malpractice Case Against Akin

    A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

  • February 06, 2026

    Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit

    Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.

  • February 06, 2026

    Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case

    A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    NJ Judge Tosses Pacira Investor Suit Over Patent Loss

    A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.

  • February 06, 2026

    Arizona Abortion Restrictions Found Unconstitutional

    An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.

  • February 06, 2026

    PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test

    The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.

  • February 06, 2026

    3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study

    Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court. 

  • February 06, 2026

    TPG Hid Exactech Defects To Dodge Liability, Trust Alleges

    The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    Beasley Allen Disqualified From NJ Talc Multicounty Litigation

    A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.

  • February 06, 2026

    Insulet Gets $14.9M Fee Award For Trade Secret Trial Win

    A Massachusetts federal judge awarded Insulet Corp.'s attorneys almost $15 million for their $452 million jury trial victory in a trade secrets dispute that was later reduced to $59.4 million, but the fees Goodwin Procter LLP netted were significantly less than the nearly $25 million it requested.

  • February 06, 2026

    FLSA Does Not Bar Claim Waivers, Wash. Judge Says

    The Fair Labor Standards Act does not categorically bar a contract's release of an employee's claims, a Washington federal judge ruled, finding that a former pharmaceutical manufacturing company worker's severance agreement that included a general release of claims precludes his wage suit.

  • February 06, 2026

    HHS Ends 340B Drug Rebate Pilot After Legal Challenge

    The U.S. Department of Health and Human Services has ended a proposed rebate program that would have altered how hospitals receive payments for participating in the federal 340B drug discount program, which provides discounted prescription drugs for low-income Americans, after facing a lawsuit from a major hospital association.

  • February 05, 2026

    NYAG's Insider Trading Case A Power Grab, Judge Told

    The former CEO of healthcare contractor Emergent BioSolutions Inc. has removed to federal court New York Attorney General Letitia James' insider trading case against him, alleging James is trying to expand her office's power through claims that concern questions of federal law.

  • February 05, 2026

    Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax

    The full Federal Circuit won't rethink a panel's refusal to revive claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy that a lower court found were invalid.

  • February 05, 2026

    Judge Affirms Health Cos.' Sanctions For Witness Omission

    An Illinois federal judge rejected a "vague and unsupported" bid by a home healthcare company accused of violating federal kickback laws to reconsider sanctions she ordered for failing to disclose witnesses, saying the motion "wastes everyone's time" and scolding the defendants for "impugning the character and professionalism of an able magistrate judge."

  • February 05, 2026

    David Protein Gets Ingredient Supply Antitrust Claims Tossed

    A New York federal court dismissed a lawsuit from several low-calorie food producers accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after it purchased the ingredient's only supplier.

  • February 05, 2026

    Patent Co., AI Research Firm Join Forces In $150M Deal

    Patent monetization venture SIM IP has announced a merger valued at $150 million with artificial intelligence research firm Garden Intel, a deal the companies said would create a first-of-its-kind platform.

Expert Analysis

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

  • Trends In Post-Grant Practice Since USPTO Denial Guidance

    Author Photo

    Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.